Diabetes & Obesity Pharmaceutical and Healthcare Pipeline Review H2

WiseGuyReports.com adds “Diabetes & Obesity Drug Development Pipeline Review, 2016” reports to its database.

Diabetes & Obesity Drug

 

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

 

Get Sample Report @ https://www.wiseguyreports.com/sample-request/758253-diabetes-obesity-drug-development-pipeline-review-2016

 

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.

 

Scope

– Which companies are the most active within the pipeline for diabetes and obesity?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?

– What are the most important R&D milestones and data publications to have occurred in this disease area?

 

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.

– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.

– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.

– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

 

Table of Contents

Table of Contents 4

List of Tables 6

List of Figures 22

Diabetes and Obesity Report Coverage 24

Type 1 Diabetes (Juvenile Diabetes) Overview 24

Type 2 Diabetes Overview 24

Obesity Overview 24

Therapeutics Development by Stage 25

Type 1 diabetes (Juvenile Diabetes) 25

Type 2 Diabetes 27

Obesity 29

Therapeutics under Development by Companies 31

Type 1 Diabetes (Juvenile Diabetes) 31

Type 2 Diabetes 41

Obesity 61

Therapeutics under Investigation by Universities/Institutes 70

Type 1 diabetes (Juvenile Diabetes) 70

Type 2 Diabetes 72

Obesity 75

Pipeline Products Glance 78

Type 1 diabetes (Juvenile Diabetes) 78

Type 2 Diabetes 81

Obesity 84

Products under Development by Companies 87

Type 1 diabetes (Juvenile Diabetes) 87

Type 2 Diabetes 98

Obesity 121

Products under Investigation by Universities/Institutes 130

Type 1 diabetes (Juvenile Diabetes) 130

Type 2 Diabetes 133

Obesity 139

Companies Involved in Therapeutics Development 143

 

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 25

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 26

Number of Products under Development for Type 2 Diabetes, H2 2016 27

Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 28

Number of Products under Development for Obesity, H2 2016 29

Number of Products under Development for Obesity – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 32

Number of Products under Development by Companies, H2 2016 (Contd..1) 33

Number of Products under Development by Companies, H2 2016 (Contd..2) 34

Number of Products under Development by Companies, H2 2016 (Contd..3) 35

Number of Products under Development by Companies, H2 2016 (Contd..4) 36

…Continued

 

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 25

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 26

Number of Products under Development for Type 2 Diabetes, H2 2016 27

Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 28

Number of Products under Development for Obesity, H2 2016 29

Number of Products under Development for Obesity – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Development by Companies, H2 2016 41

Number of Products under Development by Companies, H2 2016 61

Number of Products under Investigation by Universities/Institutes, H2 2016 70

…Continued

 

Access Report @ https://www.wiseguyreports.com/reports/758253-diabetes-obesity-drug-development-pipeline-review-2016

                                                                                                                              

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States
Website: www.wiseguyreports.com